Upcoming trial readouts
All · Readouts · AdComm · Recent approvals
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-08-06 today
ESTIMATED |
READOUT
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderat
Phase 3 · Plaque Psoriasis |
AMGN AMGEN INC | Apremilast |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-06 today
ESTIMATED |
READOUT
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to S
Phase 2 · Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis |
Merck Sharp & Dohme LLC | Efinopegdutide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-07 in 1d
ESTIMATED |
READOUT
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizum
Phase 3 · Axial Spondyloarthritis, Ankylosing Spondylitis |
UCB Biopharma SRL | Bimekizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-08 in 2d
ESTIMATED |
READOUT
A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric P
Phase 3 · Yellow Fever Immunization |
SNY Sanofi | Yellow fever vaccine (live), Yellow feve |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-10 in 4d
ESTIMATED |
READOUT
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Seve
Phase 2/3 · Generalized Myasthenia Gravis |
UCB Biopharma SRL | rozanolixizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-10 in 4d
ESTIMATED |
READOUT
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Pa
Phase 3 · NonSegmental Vitiligo |
INCY INCYTE CORP | Ruxolitinib Cream, Vehicle Cream |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-12 in 6d
ESTIMATED |
READOUT
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects Wi
Phase 2 · Ovarian Cancer |
USWM CT, LLC | Autologous genetically modified ADP-A2M4 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-12 in 6d
ESTIMATED |
READOUT
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-03
Phase 3 · Hyperlipidemia |
Merck Sharp & Dohme LLC | Enlicitide, Rosuvastatin |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-13 in 7d
ESTIMATED |
READOUT
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical
Phase 2 · Urticaria Chronic |
JSPR Jasper Therapeutics, Inc. | Briquilimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-13 in 7d
ESTIMATED |
READOUT
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity a
Phase 2 · Overweight, Type 2 Diabetes |
Zealand Pharma | Petrelintide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-13 in 7d
ESTIMATED |
READOUT
Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidia
Phase 3 · Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital |
pH-D Feminine Health LLC | Boric acid |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-14 in 8d
ESTIMATED |
READOUT
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to
Phase 3 · Erosive Esophagitis |
AZN ASTRAZENECA PLC | Nexium 20mg, Nexium 10mg |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-14 in 8d
ESTIMATED |
READOUT
Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.
Phase 4 · Diabetic Foot Ulcer (DFU), Amnio-Maxx |
Royal Biologics | Amnio-Maxx® Dual Layer Amnion Patch |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-15 in 9d
ESTIMATED |
READOUT
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years Wi
Phase 2/3 · Hemophilia |
Genzyme, a Sanofi Company | Fitusiran |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-15 in 9d
ESTIMATED |
READOUT
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP5
Phase 1/2 · Advanced Solid Tumor, Advanced Malignant Neoplasm |
PMVP PMV Pharmaceuticals, Inc. | rezatapopt, pembrolizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-17 in 11d
ESTIMATED |
READOUT
Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parki
Phase 2 · Parkinson Disease, Multiple System Atrophy |
BioArctic AB | exidavnemab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-17 in 11d
ESTIMATED |
READOUT
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Stud
Phase 2 · Chronic Obstructive Pulmonary Disease |
Verona Pharma, Inc., a subsidiary | Ensifentrine 3 mg, Glycopyrrolate 21.25 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-18 in 12d
ESTIMATED |
READOUT
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancer
Phase 2 · Gastrointestinal Cancer |
Merck Sharp & Dohme LLC | Raludotatug Deruxtecan (R-DXd) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-19 in 13d
ESTIMATED |
READOUT
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With
Phase 3 · Sjogren's Syndrome |
AMGN AMGEN INC | Dazodalibep |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-19 in 13d
ESTIMATED |
READOUT
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + R
Phase 3 · HIV Infections |
ViiV Healthcare | CAB LA + RPV LA, Oral ART |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-20 in 14d
ESTIMATED |
READOUT
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps Peop
Phase 2 · Chronic Kidney Disease |
Boehringer Ingelheim | Vicadrostat, Empagliflozin |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-21 in 15d
ESTIMATED |
READOUT
Avelumab Program Rollover Study
Phase 3 · Solid Tumors |
EMD Serono Research & Development | Avelumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-21 in 15d
ESTIMATED |
READOUT
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participan
Phase 1/2 · Carcinoma, Renal Cell |
Merck Sharp & Dohme LLC | Pembrolizumab, Favezelimab/Pembrolizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-21 in 15d
ESTIMATED |
READOUT
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participan
Phase 1/2 · Carcinoma, Renal Cell |
Merck Sharp & Dohme LLC | Pembrolizumab, MK-4830, Belzutifan, Lenv |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-21 in 15d
ESTIMATED |
READOUT
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults
Phase 3 · Dravet Syndrome |
Longboard Pharmaceuticals | LP352 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-21 in 15d
ESTIMATED |
READOUT
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in
Phase 2 · Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy |
NVO NOVO NORDISK A S | CagriSema (Cagrilintide B and Semaglutid |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-21 in 15d
ESTIMATED |
READOUT
Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide
Phase 2 · Obesity |
NodThera Limited | NT-0796 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-23 in 17d
ESTIMATED |
READOUT
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination Wit
Phase 1/2 · Breast Cancer, Solid Tumors |
PFE PFIZER INC | PF-07220060 + PF-07104091 combination do |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-24 in 18d
ESTIMATED |
READOUT
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbocic
Phase 3 · ER-Positive HER2-Negative Breast Cancer |
AZN ASTRAZENECA PLC | AZD9833, Anastrozole, Anastrozole placeb |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-24 in 18d
ESTIMATED |
READOUT
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Compl
Phase 3 · Paroxysmal Nocturnal Hemoglobinuria |
Alexion Pharmaceuticals, Inc. | Danicopan |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-24 in 18d
ESTIMATED |
READOUT
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Phar
Phase 2 · Obesity, Overweight |
Hoffmann-La Roche | RO7204239, RO7204239 Matching Placebo, T |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-25 in 19d
ESTIMATED |
READOUT
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastom
Phase 2 · Glioblastoma, Glioblastoma Multiforme |
BPGbio | BPM31510, Vitamin K1, Temozolomide (TMZ) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-25 in 19d
ESTIMATED |
READOUT
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanc
Phase 3 · Non-Small Cell Lung Cancer |
NVS NOVARTIS AG | JDQ443, docetaxel |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-25 in 19d
ESTIMATED |
READOUT
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Partici
Phase 2 · Graves' Disease |
SNY Sanofi | Rilzabrutinib dose 1, Rilzabrutinib dose |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-26 in 20d
ESTIMATED |
READOUT
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular D
Phase 2 · Duchenne Muscular Dystrophy |
Hoffmann-La Roche | Satralizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-27 in 21d
ESTIMATED |
READOUT
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Phase 1/2 · Prostate Cancer, Metastatic Castration-resistant Prostate Cancer |
Blue Earth Therapeutics Ltd | Lutetium (177Lu) rhPSMA-10.1 Injection, |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-27 in 21d
ESTIMATED |
READOUT
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
Phase 4 · Diabetes Mellitus, Type 1 |
SNY Sanofi | teplizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-28 in 22d
ESTIMATED |
READOUT
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With
Phase 1/2 · Non-Small-Cell Lung Carcinoma |
AZN ASTRAZENECA PLC | AZD2936 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-28 in 22d
ESTIMATED |
READOUT
A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
Phase 2 · Endometrial Cancer |
Hoffmann-La Roche | Giredestrant |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-28 in 22d
ESTIMATED |
READOUT
A Study to See How Well and How Safely Different Treatments Work in a Group of P
Phase 1/2 · Non-Small Cell Lung Cancer |
Hoffmann-La Roche | Alectinib, Cisplatin, Carboplatin, Pemet |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-28 in 22d
ESTIMATED |
READOUT
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injectio
Phase 2 · Knee Osteoarthritis, Synovitis of Knee |
4Moving Biotech | 4P004 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-29 in 23d
ESTIMATED |
READOUT
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Ca
Phase 2/3 · Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma |
Panbela Therapeutics, Inc. | SBP-101, Nab-paclitaxel, Gemcitabine |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-30 in 24d
ESTIMATED |
READOUT
A Study of PTX-9908 Injection for Non-resectable HCC with TACE
Phase 1/2 · Carcinoma, Hepatocellular |
TCM Biotech International Corp. | PTX-9908 Injection |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-30 in 24d
ESTIMATED |
READOUT
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
Phase 2 · Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary |
OncoC4, Inc. | ONC-392, Pembrolizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-30 in 24d
ESTIMATED |
READOUT
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in P
Phase 3 · Multiple Myeloma |
PFE PFIZER INC | Elranatamab, Elotuzumab, Pomalidomide, D |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-30 in 24d
ESTIMATED |
READOUT
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Hea
Phase 2 · Cystic Fibrosis |
ReCode Therapeutics | RCT2100, RCT2100, RCT2100, Ivacaftor |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-30 in 24d
ESTIMATED |
READOUT
A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Gen
Phase 2 · Epilepsy, Generalized, Epilepsy, Absence |
NeuroPro Therapeutics, Inc. | NPT 2042 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-31 in 25d
ESTIMATED |
READOUT
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmaco
Phase 3 · Chronic Kidney Disease; Iron Deficiency Anemia |
AMAG Pharmaceuticals, Inc. | Ferumoxytol, Iron sucrose |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-31 in 25d
ESTIMATED |
READOUT
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Phase 2 · Pancreatic Cancer, Metastatic Pancreatic Cancer |
Astellas Pharma Global Development | zolbetuximab, nab-paclitaxel, gemcitabin |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-31 in 25d
ESTIMATED |
READOUT
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Derm
Phase 3 · Moderate-to-Severe Atopic Dermatitis |
Galderma R&D | Nemolizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-31 in 25d
ESTIMATED |
READOUT
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-
Phase 3 · Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma |
Daiichi Sankyo | Trastuzumab deruxtecan, Ramucirumab, Pac |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-31 in 25d
ESTIMATED |
READOUT
rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Di
Phase 1/2 · Canavan Disease |
Myrtelle Inc. | rAAV-Olig001-ASPA, Levetiracetam, Predni |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-31 in 25d
ESTIMATED |
READOUT
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Particip
Phase 3 · Stereotypical Prolonged Seizures |
UCB Biopharma SRL | Staccato alprazolam |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-31 in 25d
ESTIMATED |
READOUT
LMN-201 for Prevention of C. Difficile Infection Recurrence
Phase 2/3 · Clostridioides Difficile Infection |
Lumen Bioscience, Inc. | LMN-201 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-31 in 25d
ESTIMATED |
READOUT
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) T
Phase 2 · Pulmonary Embolism |
Translational Sciences, Inc. | TS23 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-31 in 25d
ESTIMATED |
READOUT
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel
Phase 1/2 · KRAS Activating Mutation, Metastatic Cancer |
VSTM Verastem, Inc. | avutometinib (VS-6766) and defactinib in |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-31 in 25d
ESTIMATED |
READOUT
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Partici
Phase 3 · Primary IgA Nephropathy |
Hoffmann-La Roche | Sefaxersen (RO7434656) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-31 in 25d
ESTIMATED |
READOUT
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Ag
Phase 2 · Neovascular Age-Related Macular Degeneration (nAMD) |
Kyowa Kirin Co., Ltd. | KHK4951, Aflibercept Injection |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-31 in 25d
ESTIMATED |
READOUT
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macul
Phase 2 · Diabetic Macular Edema (DME) |
Kyowa Kirin Co., Ltd. | KHK4951, Aflibercept Injection |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-31 in 25d
ESTIMATED |
READOUT
A Phase IIa Study to Evaluate NBQ72S
Phase 2 · Breast Cancer |
Nantong Bencao Quadriga Medical Te | NBQ72S |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-31 in 25d
ESTIMATED |
READOUT
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment
Phase 3 · Osteosarcoma |
Hansoh BioMedical R&D Company | HS-20093, Gemcitabine combined with doce |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-31 in 25d
ESTIMATED |
READOUT
A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults
Phase 3 · Respiratory Syncytial Virus (RSV) |
PFE PFIZER INC | RSVpreF |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
Phase 3 · Ulcerative Colitis |
Alfasigma S.p.A. | Filgotinib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chro
Phase 2 · Chronic Hepatitis B |
GILD GILEAD SCIENCES, INC. | TAF |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair
Phase 3 · Stress Urinary Incontinence |
Cook MyoSite | AMDC-USR (iltamiocel) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Particip
Phase 2 · Myelofibrosis |
KPTI Karyopharm Therapeutics Inc. | Selinexor, Physician's Choice Treatment |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Su
Phase 3 · Primary Immune Deficiency |
Octapharma | Newnorm |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Di
Phase 3 · Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm |
VNDA Vanda Pharmaceuticals Inc. | Tasimelteon |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
Phase 4 · Migraine Disorders |
Upsher-Smith Laboratories | Qudexy XR |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-01 in 26d
ESTIMATED |
READOUT
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-interm
Phase 3 · Diffuse Large B-cell Lymphoma |
INCY INCYTE CORP | Tafasitamab, Lenalidomide, Rituximab, Cy |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-e
Phase 1/2 · Prostatic Neoplasms, Castration-Resistant |
Clarity Pharmaceuticals Ltd | 64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participa
Phase 2 · Non-small Cell Lung Cancer |
GILD GILEAD SCIENCES, INC. | Sacituzumab Govitecan-hziy (SG), Pembrol |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
Phase 2 · Becker Muscular Dystrophy |
EWTX Edgewise Therapeutics, Inc. | Sevasemten 10 mg, Sevasemten 5 mg, Sevas |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric
Phase 3 · Schizophrenia, Bipolar I Disorder |
ALKS Alkermes plc. | OLZ/SAM, Olanzapine |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HE
Phase 1/2 · Solid Tumors |
ORIC Oric Pharmaceuticals, Inc. | ORIC-114, Chemotherapy drug |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Study to Assess SLN124 in Patients With Polycythemia Vera
Phase 1/2 · Polycythemia Vera |
SLN Silence Therapeutics plc | SLN124 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity an
Phase 2 · Overweight, Obesity |
LLY ELI LILLY & Co | Tirzepatide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-01 in 26d
ESTIMATED |
READOUT
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given
Phase 1/2 · Breast Cancer |
PFE PFIZER INC | ARV-471, Abemaciclib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-01 in 26d
ESTIMATED |
READOUT
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pedia
Phase 3 · Irritable Bowel Syndrome With Constipation (IBS-C) |
ARDX ARDELYX, INC. | Tenapanor 50 MG, Tenapanor 25 mg bid |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Is
Phase 3 · Acute Ischemic Stroke, Cerebral Stroke |
Pharmazz, Inc. | Drug: Normal Saline, Sovateltide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular D
Phase 2/3 · Duchenne Muscular Dystrophy |
RGNX REGENXBIO Inc. | RGX-202 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head
Phase 1/2 · Head Neck Cancer, Intratumoral Injection |
Coordination Pharmaceuticals, Inc. | RiMO-301 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-tra
Phase 2 · Motion Sickness, Space, Motion Simulation |
Repurposed Therapeutics, Inc. | DPI-386 Nasal Gel, Other (e.g., prometha |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Phase 1/2 · Non Small Cell Lung Cancer, Solid Tumors, Adult |
TNGX Tango Therapeutics, Inc. | TNG260, Pembrolizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Maligna
Phase 1/2 · Advanced Solid Malignancies |
Georgiamune Inc | GIM122 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-ri
Phase 3 · Prostate Cancer, Prostatic Neoplasms |
Clarity Pharmaceuticals Ltd | 64Cu-SAR-bisPSMA |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-01 in 26d
ESTIMATED |
READOUT
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in
Phase 2 · Neoplasms, Head and Neck |
GlaxoSmithKline | Dostarlimab, Belrestotug, Nelistotug, Re |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prosta
Phase 4 · Prostate Cancer |
Lantheus Medical Imaging | Piflufolastat F 18 Intravenous Solution |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Y
Phase 2 · Thyroid Eye Disease |
Tourmaline Bio, Inc., a Novartis C | TOUR006 - 20 MG, TOUR006 - 50 MG |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug M
Phase 3 · Juvenile Psoriatic Arthritis |
ABBV AbbVie Inc. | Adalimumab, Risankizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic St
Phase 2 · Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH) |
CORT CORCEPT THERAPEUTICS INC | Miricorilant (Cohort A), Miricorilant (C |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-01 in 26d
ESTIMATED |
READOUT
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (
Phase 3 · Dravet Syndrome |
UCB BIOSCIENCES, Inc. | fenfluramine |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary
Phase 2 · Idiopathic Pulmonary Fibrosis |
SNDX Syndax Pharmaceuticals Inc | Axatilimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Phase 3 · Prostate Cancer, Prostate Adenocarcinoma |
Curium US LLC | Copper Cu 64 PSMA I&T |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosi
Phase 2 · Secondary Progressive Multiple Sclerosis |
TLSA Tiziana Life Sciences Ltd | Foralumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (
Phase 3 · Perennial Allergic Rhinitis (PAR) |
LLY ELI LILLY & Co | LY3650150, Standard therapy for INCS |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses St
Phase 1/2 · Alpha-1 Antitrypsin Deficiency |
WVE Wave Life Sciences Ltd. | WVE-006 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
A Study of AMDX-2011P in Participants With Alzheimer's Disease
Phase 2 · Alzheimer Disease |
Amydis Inc. | AMDX-2011P |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metast
Phase 2 · Breast Cancer, TNBC - Triple-Negative Breast Cancer |
PCSA Processa Pharmaceuticals, In | PCS6422 and capecitabine, Capecitabine |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-01 in 26d
ESTIMATED |
READOUT
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130
Phase 2 · Chronic Kidney Disease |
NVO NOVO NORDISK A S | NNC0519-0130, Semaglutide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults
Phase 3 · Multifocal Motor Neuropathy (MMN), MMN |
ARGX ARGENX SE | Empasiprubart, IVIG (Intravenous Immunog |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of S
Phase 2 · Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) |
CYTK CYTOKINETICS INC | CK-4021586 (150 mg, 300 mg, 450 mg, and |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
Phase 2 · Proteinuric Kidney Disease |
MAZE Maze Therapeutics, Inc. | MZE829 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Phase 3 · Gout, Arthritis, Gouty |
Arthrosi Therapeutics | AR882 50 mg, AR882 75 mg |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HC
Phase 3 · HEPATITIS C VIRUS CHRONIC INFECTION |
AVIR Atea Pharmaceuticals, Inc. | Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosb |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
Phase 3 · Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) |
IRON Disc Medicine, Inc. | DISC-1459 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Rig
Phase 3 · Right-To-Left Shunt |
Agitated Solutions, Inc. | Agitated Saline SoC, ASI-02 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of H
Phase 2 · Antioxidant Absorption |
NAMS NewAmsterdam Pharma Co N.V. | Obicetrapib 10mg |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Monthly Dosing of Atacicept in IgAN
Phase 2 · IgA Nephropathy (IgAN), Berger Disease |
VERA Vera Therapeutics, Inc. | Atacicept |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
Phase 2 · Fuchs Endothelial Corneal Dystrophy, Fuchs |
DSGN Design Therapeutics, Inc. | DT-168 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
Phase 2 · Nonfluent Variant Primary Progressive Aphasia (nfvPPA) |
EIP Pharma Inc | Neflamapimod |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With B
Phase 2 · Bipolar 1 Disorder |
RAPP Rapport Therapeutics, Inc. | RAP-219 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Sev
Phase 2 · Onychomycosis of Toenail |
VNDA Vanda Pharmaceuticals Inc. | Trichostatin A |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
A Study in Subjects With Neurogenic Orthostatic Hypotension
Phase 2 · Neurogenic Orthostatic Hypotension |
CuraSen Therapeutics, Inc. | CST-3056 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to P
Phase 2 · Dry Eye |
VNDA Vanda Pharmaceuticals Inc. | VSJ-110 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced
Phase 1/2 · Neoplasms |
CORT CORCEPT THERAPEUTICS INC | Nenocorilant 200 mg, Nenocorilant 300 mg |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Taldefgrobep Alfa in Adults With Overweight and Obesity
Phase 2 · Obesity, Overweight |
BHVN Biohaven Ltd. | Taldefgrobep Alfa, Taldefgrobep Alfa |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on
Phase 2 · Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG) |
Qlaris Bio, Inc. | QLS-111 Ophthalmic Solution (0.015%), QL |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
Phase 2 · Obese, Obesity |
Gasherbrum Bio, Inc., a wholly own | Aleniglipron |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepha
Phase 2 · Demodex Blepharitis |
GKOS GLAUKOS Corp | GLK-321 low dose BID, GLK-321 mid dose B |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-02 in 27d
ESTIMATED |
READOUT
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult Pe
Phase 1/2 · Pulmonary Arterial Hypertension |
PFE PFIZER INC | PF-07868489 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-02 in 27d
ESTIMATED |
READOUT
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People Wi
Phase 3 · Lung Cancer, Non-squamous, Non-small Cell |
Boehringer Ingelheim | zongertinib, pembrolizumab, cisplatin, c |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-04 in 29d
ESTIMATED |
READOUT
A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants R
Phase 2 · Methamphetamine Intoxication, Methamphetamine Disorders |
Clear Scientific, Inc. | Methamphetamine, Sterile Saline, CS-1103 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-05 in 30d
ESTIMATED |
READOUT
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
Phase 3 · Chronic Migraine in Children |
H. Lundbeck A/S | Eptinezumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-05 in 30d
ESTIMATED |
READOUT
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Phase 1/2 · Advanced Solid Tumors |
BMY BRISTOL MYERS SQUIBB CO | BMS-986490, Bevacizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-05 in 30d
ESTIMATED |
READOUT
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (M
Phase 2 · Arthritis, Rheumatoid |
Merck Sharp & Dohme LLC | Tulisokibart, Methotrexate |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-06 in 1mo
ESTIMATED |
READOUT
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vacc
Phase 2 · COVID-19 |
CastleVax Inc. | NDV-HXP-S-KP.2, COVID-19 mRNA Vaccine |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-09 in 1mo
ESTIMATED |
READOUT
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Form
Phase 2 · HIV Infections |
ViiV Healthcare | CAB LA, New formulation of CAB LA |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-10 in 1mo
ESTIMATED |
READOUT
A Study on the Immune Response and Safety of an Investigational Chickenpox Vacci
Phase 3 · Chickenpox |
GlaxoSmithKline | Candidate varicella vaccine, Marketed va |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-11 in 1mo
ESTIMATED |
READOUT
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
Phase 2 · Duchenne Muscular Dystrophy, Exon 44 |
NS Pharma, Inc. | NS-089/NCNP-02 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-11 in 1mo
ESTIMATED |
READOUT
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uvei
Phase 3 · Uveitis, Posterior, Uveitis, Intermediate |
Priovant Therapeutics, Inc. | Brepocitinib PO QD |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-15 in 1mo
ESTIMATED |
READOUT
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond
Phase 1/2 · Hemophilia A |
Bayer | BAY2599023 (DTX201) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-15 in 1mo
ESTIMATED |
READOUT
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With
Phase 3 · Endometrial Neoplasms |
Merck Sharp & Dohme LLC | Pembrolizumab, Carboplatin, Paclitaxel, |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-15 in 1mo
ESTIMATED |
READOUT
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
Phase 2 · Cushing's Disease |
H. Lundbeck A/S | Lu AG13909 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-15 in 1mo
ESTIMATED |
READOUT
A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Dis
Phase 2 · Celiac Disease |
Teva Branded Pharmaceutical Produc | TEV-53408 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-15 in 1mo
ESTIMATED |
READOUT
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Over
Phase 1/2 · Obesity and Obesity-related Medical Conditions |
PFE PFIZER INC | MET233 and MET097, MET097 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-17 in 1mo
ESTIMATED |
READOUT
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type
Phase 3 · Type 1 Diabetes, Kidney Transplant |
Vertex Pharmaceuticals Incorporate | Biological/Vaccine |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-18 in 1mo
ESTIMATED |
READOUT
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the B
Phase 2 · Crohn's Disease |
TAK TAKEDA PHARMACEUTICAL CO LTD | TAK-279 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-18 in 1mo
ESTIMATED |
READOUT
Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polym
Phase 2/3 · SCLC |
Han Xu, M.D., Ph.D., FAPCR, Sponso | Topotecan - usual, Topotecan - study |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-19 in 1mo
ESTIMATED |
READOUT
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of F
Phase 3 · Asthma |
Teva Branded Pharmaceutical Produc | Fp/ABS, FP, ABS |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-21 in 2mo
ESTIMATED |
READOUT
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
Phase 3 · Recurrent Pericarditis |
CRDL Cardiol Therapeutics Inc. | CardiolRx |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-22 in 2mo
ESTIMATED |
READOUT
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and i
Phase 1/2 · Solid Tumor, Melanoma |
ImmVira Pharma Co. Ltd | T3011, T3011 + pembrolizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-22 in 2mo
ESTIMATED |
READOUT
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifa
Phase 1/2 · Renal Cell Carcinoma |
Merck Sharp & Dohme LLC | Belzutifan, Palbociclib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-22 in 2mo
ESTIMATED |
READOUT
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Mono
Phase 2 · Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent |
ONC BeOne Medicines Ltd. | Sonrotoclax, Zanubrutinib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-22 in 2mo
ESTIMATED |
READOUT
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 an
Phase 1/2 · Norovirus Acute Gastroenteritis |
ModernaTX, Inc. | mRNA-1403, mRNA-1405 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-23 in 2mo
ESTIMATED |
READOUT
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Ad
Phase 2 · Liposarcoma, Prostate Cancer |
PFE PFIZER INC | PF-07220060, Letrozole, Fulvestrant, Mid |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-24 in 2mo
ESTIMATED |
READOUT
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323
Phase 1/2 · Systemic Lupus Erythematosus, Lupus Nephritis |
NVS NOVARTIS AG | YTB323 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-27 in 2mo
ESTIMATED |
READOUT
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whethe
Phase 3 · Lupus Erythematosus, Systemic |
BIIB BIOGEN INC. | Litifilimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-28 in 2mo
ESTIMATED |
READOUT
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous
Phase 2 · Cutaneous Squamous Cell Carcinoma |
INCY INCYTE CORP | INCB099280 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-28 in 2mo
ESTIMATED |
READOUT
A Study of AT-02 in Subjects With Systemic Amyloidosis.
Phase 2 · Amyloidosis; Systemic |
Attralus, Inc. | AT02 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-28 in 2mo
ESTIMATED |
READOUT
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Di
Phase 2/3 · Stargardt Disease |
OCGN Ocugen, Inc. | OCU410ST |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-28 in 2mo
ESTIMATED |
READOUT
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcu
Phase 3 · Hidradenitis Suppurativa |
MLTX MoonLake Immunotherapeutics | Sonelokimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-29 in 2mo
ESTIMATED |
READOUT
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Rela
Phase 3 · Eosinophilic Granulomatosis With Polyangiitis |
GlaxoSmithKline | Depemokimab, Mepolizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-29 in 2mo
ESTIMATED |
READOUT
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Pa
Phase 2 · Asthma |
SNY Sanofi | Amlitelimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled
Phase 2/3 · Refractory Schizophrenia |
SyneuRx International (Taiwan) Cor | NaBen® |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib i
Phase 1/2 · Indolent B-Cell Non-Hodgkin Lymphoma |
BioInvent International AB | BI-1206, Rituximab, Acalabrutinib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, RO
Phase 1/2 · Locally Advanced Solid Tumors, Metastatic Solid Tumors |
TPB Turning Point Brands, Inc. | Oral repotrectinib (TPX-0005) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
Linerixibat Long-term Safety, and Tolerability Study
Phase 3 · Cholestasis |
GlaxoSmithKline | Linerixibat |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
Phase 2 · Adenovirus Infections, Cytomegalovirus Infection |
SymBio Pharmaceuticals | BCV |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whethe
Phase 3 · Lupus Erythematosus, Systemic |
BIIB BIOGEN INC. | Litifilimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Ri
Phase 2 · Lymphoma |
Hoffmann-La Roche | Glofitamab, Tocilizumab, Doxorubicin, Vi |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab
Phase 3 · Non-Small Cell Lung Cancer |
AZN ASTRAZENECA PLC | Durvalumab, Oleclumab, Monalizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors
Phase 1/2 · KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung |
NVS NOVARTIS AG | JDQ443, trametinib, Ribociclib, cetuxima |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Pati
Phase 1/2 · EGFR Mutant Advanced Non-small Cell Lung Cancer |
J Ints Bio | JIN-A02 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G
Phase 2 · Advanced NSCLC, Metastatic Lung Cancer |
Mirati Therapeutics Inc. | Adagrasib oral dose of 400 mg twice dail |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
Phase 1/2 · Congenital Adrenal Hyperplasia |
H. Lundbeck A/S | Lu AG13909 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With
Phase 2 · Recurrent Wheezing, Wheezing Lower Respiratory Illness |
OM Pharma SA | OM-85 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squam
Phase 1/2 · Non-Small Cell Lung Cancer |
EMD Serono Research & Development | M1774, Cemiplimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced S
Phase 1/2 · Advanced Solid Tumors |
BMY BRISTOL MYERS SQUIBB CO | BMS-986449, Nivolumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
Azeliragon in MGMT Unmethylated Glioblastoma
Phase 2 · Glioblastoma |
Cantex Pharmaceuticals | Azeliragon |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's
Phase 2 · Alzheimer's Disease |
GlaxoSmithKline | GSK4527226 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administer
Phase 1/2 · Amyotrophic Lateral Sclerosis |
UniQure Biopharma B.V. | AMT-162 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the B
Phase 2 · Ulcerative Colitis |
TAK TAKEDA PHARMACEUTICAL CO LTD | TAK-279 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of
Phase 2 · Basal Cell Carcinoma |
Stamford Pharmaceuticals, Inc. | SP-002, Vismodegib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as
Phase 1/2 · Extensive Stage-small Cell Lung Cancer |
Daiichi Sankyo | Ifinatamab deruxtecan, Atezolizumab, Car |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of
Phase 2/3 · Generalized Myasthenia Gravis |
ARGX ARGENX SE | Efgartigimod PH20 SC |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osime
Phase 3 · Metastatic Non-small Cell Lung Cancer |
AZN ASTRAZENECA PLC | Dato-DXd, Osimertinib, Pemetrexed, Carbo |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cel
Phase 3 · Small Cell Lung Cancer |
Hansoh BioMedical R&D Company | HS-20093, Topotecan |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
An Extension and Crossover Vaccination Study on the Immune Response and Safety o
Phase 3 · Respiratory Syncytial Virus Infections |
GlaxoSmithKline | RSVPreF3 OA vaccine |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With R
Phase 2/3 · Diabetic Macular Edema (DME) |
EyeBiotech Ltd. | Ranibizumab, EYE103 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participa
Phase 2/3 · Phosphomannomutase 2 Deficiency, PMM2-CDG |
Glycomine, Inc. | GLM101 (Part A, Double-blind), GLM101 (P |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recover
Phase 2 · Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke |
EIP Pharma Inc | Neflamapimod |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
Phase 1/2 · Hyperlipidemia; Mixed |
ARWR ARROWHEAD PHARMACEUTICALS, I | ARO-DIMERPA |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruqu
Phase 2 · Colorectal Cancer |
Kahr Bio Australia Pty Ltd | DSP107 + Atezolizumab, Fruquintinib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
Clinical Study to Collect and Analyze Dental Plaque and Oral Health Measures in
Phase 4 · Gingivitis, Plaque |
CL COLGATE PALMOLIVE CO | sodium monofluorophosphate toothpaste |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical
Phase 1/2 · Type 1 Diabetes Mellitus |
Sernova Biotherapeutics Inc. | Sernova Cell Pouch |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Y
Phase 3 · Systemic Juvenile Idiopathic Arthritis |
LLY ELI LILLY & Co | Baricitinib, Tocilizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
First-in-Human Study of ICT01 in Patients With Advanced Cancer
Phase 1/2 · Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer |
ImCheck Therapeutics, an Ipsen com | IV ICT01 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Check
Phase 1/2 · Select Advanced Solid Tumors |
IMCR Immunocore Holdings plc | Brenetafusp, Brenetafusp and pembrolizum |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Phase 2 · Melanoma, Head and Neck Squamous Cell Carcinoma |
Vyriad, Inc. | VV1, Cemiplimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advan
Phase 1/2 · High-grade Glioma, Solid Tumor, Unspecified, Child |
Laminar Pharmaceuticals | LAM561 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-01 in 2mo
ESTIMATED |
READOUT
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcuta
Phase 3 · Primary Immune Thrombocytopenia |
ARGX ARGENX SE | efgartigimod PH20 SC |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus V
Phase 3 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma |
Loxo Oncology, Inc. | Pirtobrutinib, Venetoclax, Rituximab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evalua
Phase 3 · Coronary Artery Disease |
MedTrace Pharma A/S | [O-15]-Water PET Myocardial Perfusion Im |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
Phase 3 · Plaque Psoriasis |
Organon and Co | tapinarof cream, 1% |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-01 in 2mo
ESTIMATED |
READOUT
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular De
Phase 2 · Age-Related Macular Degeneration |
NVS NOVARTIS AG | Iptacopan (LNP023) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
Phase 2 · Amyotrophic Lateral Sclerosis |
CORT CORCEPT THERAPEUTICS INC | Dazucorilant 300 mg, Dazucorilant 150 mg |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Phase 3 · AMD, nAMD |
ABBV AbbVie Inc. | ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fu
Phase 1/2 · Advanced Solid Tumors, Genital Neoplasm, Female |
Marengo Therapeutics, Inc. | STAR0602 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-01 in 2mo
ESTIMATED |
READOUT
SPEARHEAD-3 Pediatric Study
Phase 1/2 · Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) |
USWM CT, LLC | Afamitresgene autoleucel |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Phase 3 · Focal Onset Seizures |
XENE Xenon Pharmaceuticals Inc. | XEN1101 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)
Phase 2 · Respiratory Distress Syndrome, Acute |
GEn1E Lifesciences | GEn-1124 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's
Phase 1/2 · Cushing Syndrome, Cushing Disease |
CRNX Crinetics Pharmaceuticals, I | atumelnant |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subj
Phase 2/3 · Oral Squamous Cell Carcinoma |
Privo Technologies | PRV211 (Intraoperative Cisplatin System) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-01 in 2mo
ESTIMATED |
READOUT
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
Phase 2 · Acute Respiratory Distress Syndrome, Infections |
BioAegis Therapeutics Inc. | Rhu-pGSN, normal saline |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study YL201 in Patients With Selected Advanced Solid Tumors
Phase 1/2 · Advanced Solid Tumor |
MediLink Therapeutics (Suzhou) Co. | YL201 for Injection |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Phase 2/3 · Dementia Moderate, Dementia, Mild |
Actinogen Medical | Xanamem |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pe
Phase 3 · Central Precocious Puberty |
Debiopharm International SA | Debio 4326 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-01 in 2mo
ESTIMATED |
READOUT
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Part
Phase 3 · Heart Failure, Systemic Inflammation |
NVO NOVO NORDISK A S | Ziltivekimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes
Phase 3 · Type 2 Diabetes |
LLY ELI LILLY & Co | Retatrutide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory F
Phase 2/3 · Focal Epilepsy |
BHVN Biohaven Ltd. | BHV-7000, BHV-7000 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participant
Phase 2 · Alzheimer Disease |
ABOS Acumen Pharmaceuticals, Inc. | sabirnetug |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Phase 2 · Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease |
Endeavor Biomedicines, Inc. | ENV-101 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urtica
Phase 3 · Chronic Spontaneous Urticaria |
CLDX Celldex Therapeutics, Inc. | barzolvolimab, Matching placebo |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urtica
Phase 3 · Chronic Spontaneous Urticaria |
CLDX Celldex Therapeutics, Inc. | barzolvolimab, Matching placebo |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver
Phase 3 · Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) |
MIRM Mirum Pharmaceuticals, Inc. | Maralixibat |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration
Phase 3 · Wet Age Related Macular Degeneration, wAMD |
EYPT EyePoint, Inc. | EYP-1901, Aflibercept (2.0 mg) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Prel
Phase 1/2 · Alopecia Areata (AA) |
Aldena Therapeutics | ALD-102 Solution |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to
Phase 2 · Eosinophilic Esophagitis |
PHAT Phathom Pharmaceuticals, Inc | Vonoprazan |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
Leniolisib for Immune Dysregulation in CVID
Phase 2 · Common Variable Immunodeficiency (CVID) |
Pharming Technologies B.V. | Leniolisib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Partici
Phase 2 · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus |
Immunovant Sciences GmbH | IMVT-1402 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participan
Phase 2 · Hypertension, Uncontrolled Hypertension |
VNDA Vanda Pharmaceuticals Inc. | iloperidone |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study to Assess Anktiva in Patients With Long Covid-19.
Phase 2 · Long COVID |
IBRX ImmunityBio, Inc. | N-803 (IL-15 Superagonist) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Co
Phase 3 · Congenital Pseudarthrosis of Tibia |
Novadip Biosciences | NVD003, Iliac Crest Bone Graft |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the U
Phase 3 · Neuromuscular Agents, Peripheral Nervous System Agents |
Merz North America, Inc. | NT 201, NT 201 Placebo |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
Phase 2 · Uncontrolled Hypertension |
Retension Pharmaceuticals. Inc. | RTN-001, Matching placebo control |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study Evaluating TRIV-509 in Atopic Dermatitis
Phase 2 · Atopic Dermatitis |
Triveni Bio | TRIV-509 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With
Phase 2 · Cognitive Impairment Associated With Schizophrenia (CIAS) |
Kynexis B.V. | KYN-5356 low dose, KYN-5356 Medium Dose, |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-01 in 2mo
ESTIMATED |
READOUT
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Heal
Phase 1/2 · Norovirus |
COCP Cocrystal Pharma, Inc. | CDI-988, Snow Mountain Virus |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uvei
Phase 2 · Non-infectious Anterior Uveitis |
Novaliq GmbH | Tacrolimus ophthalmic solution |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
Study of DISC-0974-201 in Participants With IBD and Anemia
Phase 2 · Inflammatory Bowel Disease (IBD), Anemia |
IRON Disc Medicine, Inc. | DISC-0974 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Di
Phase 2 · Type 2 Diabetes |
Housey Healthcare ULC | HP-211 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Fu
Phase 4 · Dry Eye Disease (DED) |
Andover Research Eye Institute | Preservative Free Polyethylene glycol 40 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-02 in 2mo
ESTIMATED |
READOUT
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
Phase 3 · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy |
TAK TAKEDA PHARMACEUTICAL CO LTD | TAK-861 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-05 in 2mo
ESTIMATED |
READOUT
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polyc
Phase 3 · Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis |
Swedish Orphan Biovitrum | Pacritinib, Physician's Choice medicatio |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-05 in 2mo
ESTIMATED |
READOUT
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 3
Phase 1/2 · Epstein-Barr Virus Infection |
ModernaTX, Inc. | mRNA-1189 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-05 in 2mo
ESTIMATED |
READOUT
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis As
Phase 3 · Psychosis Associated With Alzheimer's Disease |
Karuna Therapeutics, Inc., a Brist | KarXT |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-06 in 2mo
ESTIMATED |
READOUT
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Part
Phase 3 · Idiopathic Pulmonary Fibrosis |
BMY BRISTOL MYERS SQUIBB CO | BMS-986278, BMS-986278 Placebo |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-07 in 2mo
ESTIMATED |
READOUT
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥
Phase 3 · Atopic Dermatitis |
REGN REGENERON PHARMACEUTICALS, I | Dupilumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-09 in 2mo
ESTIMATED |
READOUT
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants W
Phase 3 · Hidradenitis Suppurativa |
INCY INCYTE CORP | Ruxolitinib Cream, Vehicle Cream |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-09 in 2mo
ESTIMATED |
READOUT
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants W
Phase 3 · Hidradenitis Suppurativa |
INCY INCYTE CORP | Ruxolitinib Cream, Vehicle Cream |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-10 in 2mo
ESTIMATED |
READOUT
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Phase 3 · Type 2 Diabetes |
Hangzhou Zhongmei Huadong Pharmace | HDM1002 200 mg, HDM1002 400 mg |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-12 in 2mo
ESTIMATED |
READOUT
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and H
Phase 3 · Paroxysmal Nocturnal Hemoglobinuria |
REGN REGENERON PHARMACEUTICALS, I | Ravulizumab, Pozelimab, Cemdisiran, Ecul |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-12 in 2mo
ESTIMATED |
READOUT
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-98634
Phase 1/2 · Multiple Myeloma |
BMY BRISTOL MYERS SQUIBB CO | CC-92480, Tazemetostat, BMS-986158, Tram |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-12 in 2mo
ESTIMATED |
READOUT
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Particip
Phase 3 · Metastatic Castrate-sensitive Prostate Cancer |
Janssen Research & Development, LL | Apalutamide, Androgen-deprivation Therap |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-13 in 2mo
ESTIMATED |
READOUT
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Cli
Phase 1/2 · Canavan Disease |
Aspa Therapeutics | AAV9 BBP-812 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-13 in 2mo
ESTIMATED |
READOUT
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With
Phase 2 · Idiopathic Pulmonary Fibrosis |
Daewoong Pharmaceutical Co. LTD. | DWN12088 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-13 in 2mo
ESTIMATED |
READOUT
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants
Phase 1/2 · Melanoma, Hodgkin Lymphoma |
GlaxoSmithKline | Cobolimab, Dostarlimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-14 in 2mo
ESTIMATED |
READOUT
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (
Phase 3 · Chronic Rhinosinusitis With Nasal Polyps |
SNY Sanofi | Itepekimab (SAR440340), Mometasone furoa |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-15 in 2mo
ESTIMATED |
READOUT
Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
Phase 1/2 · Duchenne Muscular Dystrophy |
SLDB Solid Biosciences Inc. | SGT-001 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|